Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 7:59 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 3,925 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: HTN Clear all

Conditions: Ocular Hypertension, Glaucoma
Interventions: latanoprost 0.005%, fixed combination latanoprost-timolol, timolol 0.5%; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 418 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 1999
U.S. locations: 53
States / cities: Anaheim, California • Sacramento, California • San Francisco, California + 39 more

Conditions: Pulmonary Hypertension
Interventions: UT-15C 1 mg, UT-15C 0.25 mg, UT-15C 5 mg, Placebo; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 26
States / cities: Birmingham, Alabama • Los Angeles, California • Sacramento, California + 19 more

Conditions: Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction
Interventions: Ambrisentan, Placebo; Drug · Other
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Resistant Hypertension in Kidney Transplant Patients
Interventions: Chlorthalidone; Drug
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Pre-Eclampsia; Complicating Pregnancy, Gestational Hypertension
Interventions: Video, Text Reminder, Blood pressure threshold; Other
Lead sponsor: Ochsner Health System; Other
Eligibility: 18 Years and older · Female only
Enrollment: 296 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Hypovitaminosis D
Interventions: 25 Hydroxy- Vitamin D3 [25 (OH) D3], Placebo; Drug
Lead sponsor: Charles Drew University of Medicine and Science; Other
Eligibility: 18 Years to 70 Years
Enrollment: 330 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Diabetic Retinopathy, Diabetes Mellitus, Type 2, Glaucoma
Interventions: Behavioral Activation, Supportive Therapy; Behavioral
Lead sponsor: Wills Eye; Other
Eligibility: 21 Years and older
Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 3
States / cities: Philadelphia, Pennsylvania

Conditions: Congenital Diaphragmatic Hernia, Persistent Pulmonary Hypertension of the Newborn, Hypoxemic Respiratory Failure, Pulmonary Hypoplasia
Interventions: Milrinone, Placebo (5% Dextrose); Drug
Lead sponsor: NICHD Neonatal Research Network; Network
Eligibility: 0 Hours to 168 Hours
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 19
States / cities: Birmingham, Alabama • Palo Alto, California • Atlanta, Georgia + 15 more

Conditions: Pulmonary Arterial Hypertension
Interventions: Treprostinil Palmitil, Placebo; Drug
Lead sponsor: Insmed Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 6
States / cities: Jacksonville, Florida • Tampa, Florida • Chicago, Illinois + 2 more

Conditions: Hypertension, Obesity, Healthy Nutrition, Blood Pressure
Interventions: RN-CHeFRx; Behavioral
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years to 99 Years · Female only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Diabetes Mellitus, Type 2, Diabetes, Diabetes type2, Type2 Diabetes, Type 2 Diabetes, Type II Diabetes, Hypertension, High Blood Pressure
Interventions: DASH4D diet, comparison diet, higher sodium, lower sodium; Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Obesity, Hypertension, Pre-diabetes, Type 2 Diabetes
Interventions: Medically-tailored meals, Produce box and recipes; Other
Lead sponsor: Cleveland Clinic Akron General; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Akron, Ohio

Conditions: Hypertension, Diabetes Mellitus, Obesity
Interventions: Food as medicine; Other
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Helena, Texas

Conditions: Glaucoma
Interventions: ASP2767, Sham ASP2767, Prophylactic Regimen A, Prophylactic Regimen B, Placebo for prophylactic regimen; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Glaucoma, Ocular Hypertension, Eye Disease
Interventions: AMA0076, Placebo; Drug
Lead sponsor: Amakem, NV; Industry
Eligibility: 30 Years to 85 Years
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 6
States / cities: Artesia, California • Inglewood, California • Petaluma, California + 3 more

Conditions: Prehypertension, Hypertension
Interventions: Nebivolol, Metoprolol, Placebo, Forearm Blood Flow (FBF) response to BQ-123 (100 mol/min), FBF response to BQ-123 (100 nmol/min)+BQ-788(50 nmol/min), FBF response to Acetylcholine, FBF response to Sodium Nitroprusside, FBF response to BQ-123+BQ-788+ACh; Drug · Other
Lead sponsor: University of Colorado, Boulder; Other
Eligibility: 45 Years to 65 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Boulder, Colorado

Conditions: Hypertension
Interventions: Resource information Supplemental Nutrition Assistance Program (SNAP), community health worker (CHW), medically tailored meals; Behavioral
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Hypertension
Interventions: Pine Bark Extract (Flavangenol®); Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Stanford, California

Conditions: Hypertension, Pre-Hypertension
Interventions: DASH-4-Teens, Routine Care; Behavioral · Other
Lead sponsor: University of Cincinnati; Other
Eligibility: 11 Years to 18 Years
Enrollment: 207 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Hypertension
Interventions: acupuncture, sham needle treatment; Device
Lead sponsor: Logan College of Chiropractic; Other
Eligibility: 20 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2008
U.S. locations: 1
States / cities: Chesterfield, Missouri

Conditions: Pulmonary Hypertension
Interventions: Vasodilator testing (Inhaled Nitric Oxide), Vasodilator testing (Inhaled Epoprostenol); Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Idiopathic Intracranial Hypertension
Interventions: Presendin, Placebo; Drug
Lead sponsor: Invex Therapeutics Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 7
States / cities: Aurora, Colorado • Miami, Florida • Minneapolis, Minnesota + 4 more

Conditions: Hypertension, Resistant to Conventional Therapy
Interventions: Equivalent dose enalapril, Equivalent dose lisinopril; Drug
Lead sponsor: Memorial Health University Medical Center; Other
Eligibility: 18 Years to 79 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Savannah, Georgia

Conditions: Hypertension
Interventions: Aliskiren, Hydrochlorothiazide; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 532 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: East Hanover, New Jersey

Search by objective public record fields.

A Study of Glaucoma or Ocular Hypertension in Patients Within the United States

FREEDOM DR: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor or as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH)

Safety and Efficacy Trial to Treat Diastolic Heart Failure Using Ambrisentan

The Management of Resistant Hypertension in Kidney Transplant Patients Using Chlorthalidone

Remote Postpartum Blood Pressure Monitoring and Cardiovascular Education

To Study the Nutri-Genomic Response of Vit-D Supplementation in African-Americans

Confronting Unequal Eye Care in Pennsylvania

Milrinone in Congenital Diaphragmatic Hernia

An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH)

Preparing a Food is Medicine Intervention to Promote Healthy Eating and Blood Pressure Control

Dietary Approaches to Stop Hypertension for Diabetes

Food as Medicine: A Quasi-Randomized Control Trial of Healthy Foods for Chronic Disease Management

The Good Food Rx: Food-as-medicine Program

A Study About the Safety of ASP2767 and Whether it Helps People With Glaucoma-Related Optic Nerve Damage

Multiple Dose-escalation Study of AMA0076 in Patients With Ocular Hypertension or Primary Open-angle Glaucoma

Nebivolol and the Endothelin (ET)-1 System

Trial to Address Food Insecurity in Patients With Hypertension (SMART-FI)

Understanding Pine Bark Extract as an Alternative Treatment (UPBEAT) Study

Modifying Dietary Behavior in Adolescents With Elevated Blood Pressure

The Effect of Acupuncture on Blood Pressure and Heart Rate Variability (HRV)

Comparison of Vasodilator Response of Inhaled Epoprostenol and Inhaled Nitric Oxide

A Trial to Determine the Efficacy and Safety of Presendin in IIH

The Use of Ambulatory Blood Pressure Monitors to Assess Angiotensin Converting Enzyme Inhibitors

Aliskiren Plus HCTZ Compared to Aliskiren in Metabolic Syndrome Patients With Stage 2 Systolic Hypertension